Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancerNiamh McGivern(Edinburgh Cancer Research), Nuala McCabe(Queen's University Belfast)OncotargetDecember 20, 201710.18632/oncotarget.23524Cited by 32SaveCiteExport RISWatch citationsRelated PapersBRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents|Oncogene|2001|153